Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-102 in Bevacizumab-Resistant High Grade Glioma
NCT01663012Phase 2Completed
- Sponsor
- Lawrence D Recht
- Start
- Jul 2012
- Primary completion
- Feb 2015
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of etirinotecan pegol in high-grade glioma (HGG), sponsored by Lawrence D Recht. Started Jul 2012; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT01663012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01663012.